Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Financing Activities (2016 - 2025)

China Pharma Holdings' Cash from Financing Activities history spans 15 years, with the latest figure at -$72592.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 33.61% year-over-year to -$72592.0; the TTM value through Dec 2025 reached -$294027.0, down 770.37%, while the annual FY2025 figure was -$294027.0, 770.37% down from the prior year.
  • Cash from Financing Activities reached -$72592.0 in Q4 2025 per CPHI's latest filing, up from -$122214.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $4.6 million in Q4 2021 to a low of -$850555.0 in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $128653.4, with a median of -$41760.5 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: surged 45928.53% in 2021, then tumbled 1885.97% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $4.6 million in 2021, then tumbled by 114.55% to -$672063.0 in 2022, then soared by 104.52% to $30378.0 in 2023, then plummeted by 278.86% to -$54333.0 in 2024, then crashed by 33.61% to -$72592.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Cash from Financing Activities are -$72592.0 (Q4 2025), -$122214.0 (Q3 2025), and -$29188.0 (Q2 2025).